Conclusions.
In conclusion, in the primary analysis of the phase 2 MOONSONG study of patients with mild or moderate COVID-19 with or without risk factors for poor outcomes, bemnifosbuvir did not show any meaningful difference in antiviral activity as measured by RT-PCR from nasopharyngeal swabs compared with placebo. Despite this finding, further evaluation of clinical outcomes of bemnifosbuvir in the treatment of COVID-19 may be warranted given current uncertainty around the negative predictive value of viral load reduction for clinical outcomes in COVID-19.